Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Onconova appoints Mark Gelder as CMO » 08:05
06/01/21
06/01
08:05
06/01/21
08:05
ONTX

Onconova

$6.68 /

-0.41 (-5.78%)

Onconova Therapeutics…

Onconova Therapeutics announced that Mark Gelder, M.D. will be joining Onconova as CMO, effective as of June 14, 2021. He was most recently the CMO of Elevar Therapeutics, where he led the company's clinical development, medical affairs, regulatory affairs, and preclinical teams.

ShowHide Related Items >><<
ONTX Onconova
$6.68 /

-0.41 (-5.78%)

ONTX Onconova
$6.68 /

-0.41 (-5.78%)

05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
  • 11
    Feb
ONTX Onconova
$6.68 /

-0.41 (-5.78%)

On The Fly
Fly Intel: Wall Street's top stories for Friday » 16:44
05/21/21
05/21
16:44
05/21/21
16:44
DE

Deere

$359.98 /

+4.91 (+1.38%)

, PANW

Palo Alto Networks

$362.62 /

+19.62 (+5.72%)

, KSU

Kansas City Southern

$294.99 /

+1.4 (+0.48%)

, CNI

Canadian National

$104.33 /

-2.05 (-1.93%)

, CP

Canadian Pacific

$81.03 /

+0.45 (+0.56%)

, T

AT&T

$30.02 /

+0.38 (+1.28%)

, GSK

GlaxoSmithKline

$38.84 /

-0.2 (-0.51%)

, VIR

Vir Biotechnology

$45.25 /

+0.27 (+0.60%)

, KO

Coca-Cola

$54.62 /

-0.04 (-0.07%)

, GM

General Motors

$56.72 /

+1.21 (+2.18%)

, VOSO

Virtuoso Acquisition

$9.70 /

+0.07 (+0.73%)

, ANVS

Annovis Bio

$59.01 /

+32.53 (+122.85%)

, YALA

Yalla

$16.90 /

+0.96 (+6.02%)

, FL

Foot Locker

$60.88 /

+1.17 (+1.96%)

, ONTX

Onconova

$9.22 /

-1.691 (-15.50%)

, VFC

VF Corp.

$77.23 /

-7.6 (-8.96%)

The major averages had a…

ShowHide Related Items >><<
YALA Yalla
$16.90 /

+0.96 (+6.02%)

VIR Vir Biotechnology
$45.25 /

+0.27 (+0.60%)

VFC VF Corp.
$77.23 /

-7.6 (-8.96%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.62 /

+19.62 (+5.72%)

ONTX Onconova
$9.22 /

-1.691 (-15.50%)

KSU Kansas City Southern
$294.99 /

+1.4 (+0.48%)

KO Coca-Cola
$54.62 /

-0.04 (-0.07%)

GSK GlaxoSmithKline
$38.84 /

-0.2 (-0.51%)

GM General Motors
$56.72 /

+1.21 (+2.18%)

FL Foot Locker
$60.88 /

+1.17 (+1.96%)

DE Deere
$359.98 /

+4.91 (+1.38%)

CP Canadian Pacific
$81.03 /

+0.45 (+0.56%)

ANVS Annovis Bio
$59.01 /

+32.53 (+122.85%)

DE Deere
$359.98 /

+4.91 (+1.38%)

05/14/21 Citi
Deere price target raised to $415 from $400 at Citi
05/13/21
Fly Intel: Top five analyst downgrades
05/13/21 Baird
Deere price target raised to $425 from $375 at Baird
05/13/21 BMO Capital
Deere downgraded to Market Perform from Outperform at BMO Capital
PANW Palo Alto Networks
$362.62 /

+19.62 (+5.72%)

05/21/21 Northland
Palo Alto Networks price target raised to $440 from $420 at Northland
05/21/21 Raymond James
Palo Alto Networks price target raised to $410 from $400 at Raymond James
05/21/21 Deutsche Bank
Palo Alto Networks price target raised to $410 from $395 at Deutsche Bank
05/21/21 JPMorgan
Palo Alto Networks price target raised to $350 from $317 at JPMorgan
KSU Kansas City Southern
$294.99 /

+1.4 (+0.48%)

05/14/21 Stephens
Canadian rail that loses KCS likely to pursue an Eastern rail, says Stephens
05/14/21 Citi
Citi sees Canadian National, Kansas City Southern deal as most likely outcome
04/26/21 Deutsche Bank
Kansas City Southern price target raised to $300 from $212 at Deutsche Bank
04/26/21 Susquehanna
Canadian Pacific will have to raise bid to win KSU war, says Susquehanna
CNI Canadian National
$104.33 /

-2.05 (-1.93%)

05/18/21 Vertical Research
Canadian National upgraded to Buy from Hold at Vertical Research
04/27/21 CIBC
Canadian National price target lowered to C$146 from C$148 at CIBC
CP Canadian Pacific
$81.03 /

+0.45 (+0.56%)

05/18/21
Fly Intel: Top five analyst downgrades
05/18/21 National Bank
Canadian Pacific downgraded to Sector Perform from Outperform at National Bank
05/17/21 Raymond James
Canadian Pacific price target updated to reflect 5-for-1 split at Raymond James
05/17/21 Scotiabank
Canadian Pacific price target updated to reflect 5-for-1 split at Scotiabank
T AT&T
$30.02 /

+0.38 (+1.28%)

05/21/21
Fly Intel: Top five analyst upgrades
05/21/21 New Street
New Street upgrades AT&T on 'tactical' call despite long-term concerns
05/21/21 New Street
AT&T upgraded to Buy from Neutral at New Street
05/21/21 UBS
AT&T upgraded to Buy from Neutral at UBS
GSK GlaxoSmithKline
$38.84 /

-0.2 (-0.51%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
VIR Vir Biotechnology
$45.25 /

+0.27 (+0.60%)

03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
03/03/21 Goldman Sachs
Vir Biotechnology price target lowered to $59 from $61 at Goldman Sachs
03/03/21 H.C. Wainwright
Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
KO Coca-Cola
$54.62 /

-0.04 (-0.07%)

05/14/21 Wells Fargo
Wells says Coca-Cola Energy discontinuation may 'rekindle' Monster M&A debate
05/14/21 Evercore ISI
Coke Energy discontinuation a 'small positive' for Monster, says Evercore ISI
04/20/21 Evercore ISI
Evercore raises Coca-Cola price target to $63, sees 'best' outlook 'in years'
04/20/21 Citi
Coca-Cola price target raised to $57 from $54 at Citi
GM General Motors
$56.72 /

+1.21 (+2.18%)

05/18/21 Tudor Pickering
GM 'well positioned' to lean into electrification trend, says Tudor Pickering
05/18/21 Tudor Pickering
General Motors initiated with a Buy at Tudor Pickering
05/18/21 Argus
General Motors price target raised to $66 from $62 at Argus
05/06/21 Deutsche Bank
General Motors price target raised to $70 from $67 at Deutsche Bank
VOSO Virtuoso Acquisition
$9.70 /

+0.07 (+0.73%)

ANVS Annovis Bio
$59.01 /

+32.53 (+122.85%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
06/18/20 Maxim
Annovis Bio initiated with a Buy at Maxim
YALA Yalla
$16.90 /

+0.96 (+6.02%)

03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform on valuation at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform at Oppenheimer
FL Foot Locker
$60.88 /

+1.17 (+1.96%)

05/19/21 B. Riley
Foot Locker price target raised to $73 from $68 at B. Riley
05/18/21 Pivotal Research
Foot Locker price target raised to $76 from $61 at Pivotal Research
05/06/21 Citi
Foot Locker price target raised to $72 from $60 at Citi
04/08/21 Cowen
Foot Locker price target raised to $72 from $70 at Cowen
ONTX Onconova
$9.22 /

-1.691 (-15.50%)

05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
VFC VF Corp.
$77.23 /

-7.6 (-8.96%)

03/08/21 Pivotal Research
VF Corp. upgraded to Buy from Hold at Pivotal Research
02/22/21 Cowen
VF Corp. business positioned well for recovery, says Cowen
01/28/21 Deutsche Bank
VF Corp. price target lowered to $99 from $103 at Deutsche Bank
01/25/21 Cowen
VF Corp. price target raised to $99 from $91 at Cowen
VFC VF Corp.
$77.23 /

-7.6 (-8.96%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.62 /

+19.62 (+5.72%)

KSU Kansas City Southern
$294.99 /

+1.4 (+0.48%)

KO Coca-Cola
$54.62 /

-0.04 (-0.07%)

GSK GlaxoSmithKline
$38.84 /

-0.2 (-0.51%)

GM General Motors
$56.72 /

+1.21 (+2.18%)

FL Foot Locker
$60.88 /

+1.17 (+1.96%)

DE Deere
$359.98 /

+4.91 (+1.38%)

CP Canadian Pacific
$81.03 /

+0.45 (+0.56%)

CNI Canadian National
$104.33 /

-2.05 (-1.93%)

  • 11
    Feb
  • 30
    Sep
  • 08
    Jul
YALA Yalla
$16.90 /

+0.96 (+6.02%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.62 /

+19.62 (+5.72%)

KSU Kansas City Southern
$294.99 /

+1.4 (+0.48%)

KO Coca-Cola
$54.62 /

-0.04 (-0.07%)

GSK GlaxoSmithKline
$38.84 /

-0.2 (-0.51%)

GM General Motors
$56.72 /

+1.21 (+2.18%)

DE Deere
$359.98 /

+4.91 (+1.38%)

CNI Canadian National
$104.33 /

-2.05 (-1.93%)

VIR Vir Biotechnology
$45.25 /

+0.27 (+0.60%)

VFC VF Corp.
$77.23 /

-7.6 (-8.96%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.62 /

+19.62 (+5.72%)

KSU Kansas City Southern
$294.99 /

+1.4 (+0.48%)

KO Coca-Cola
$54.62 /

-0.04 (-0.07%)

GSK GlaxoSmithKline
$38.84 /

-0.2 (-0.51%)

GM General Motors
$56.72 /

+1.21 (+2.18%)

FL Foot Locker
$60.88 /

+1.17 (+1.96%)

DE Deere
$359.98 /

+4.91 (+1.38%)

YALA Yalla
$16.90 /

+0.96 (+6.02%)

VFC VF Corp.
$77.23 /

-7.6 (-8.96%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.62 /

+19.62 (+5.72%)

KSU Kansas City Southern
$294.99 /

+1.4 (+0.48%)

KO Coca-Cola
$54.62 /

-0.04 (-0.07%)

GSK GlaxoSmithKline
$38.84 /

-0.2 (-0.51%)

GM General Motors
$56.72 /

+1.21 (+2.18%)

FL Foot Locker
$60.88 /

+1.17 (+1.96%)

DE Deere
$359.98 /

+4.91 (+1.38%)

CP Canadian Pacific
$81.03 /

+0.45 (+0.56%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:05
05/21/21
05/21
12:05
05/21/21
12:05
DE

Deere

$364.98 /

+9.91 (+2.79%)

, T

AT&T

$30.02 /

+0.38 (+1.28%)

, PANW

Palo Alto Networks

$362.50 /

+19.5 (+5.69%)

, VIR

Vir Biotechnology

$45.12 /

+0.14 (+0.31%)

, ANVS

Annovis Bio

$81.75 /

+55.27 (+208.72%)

, GSK

GlaxoSmithKline

$38.91 /

-0.13 (-0.33%)

, YALA

Yalla

$18.20 /

+2.26 (+14.18%)

, FL

Foot Locker

$61.49 /

+1.785 (+2.99%)

, ONTX

Onconova

$9.50 /

-1.411 (-12.93%)

, VFC

VF Corp.

$78.44 /

-6.39 (-7.53%)

The major averages are…

ShowHide Related Items >><<
YALA Yalla
$18.20 /

+2.26 (+14.18%)

VIR Vir Biotechnology
$45.12 /

+0.14 (+0.31%)

VFC VF Corp.
$78.44 /

-6.39 (-7.53%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.50 /

+19.5 (+5.69%)

ONTX Onconova
$9.50 /

-1.411 (-12.93%)

GSK GlaxoSmithKline
$38.91 /

-0.13 (-0.33%)

FL Foot Locker
$61.49 /

+1.785 (+2.99%)

DE Deere
$364.98 /

+9.91 (+2.79%)

ANVS Annovis Bio
$81.75 /

+55.27 (+208.72%)

DE Deere
$364.98 /

+9.91 (+2.79%)

05/14/21 Citi
Deere price target raised to $415 from $400 at Citi
05/13/21
Fly Intel: Top five analyst downgrades
05/13/21 Baird
Deere price target raised to $425 from $375 at Baird
05/13/21 BMO Capital
Deere downgraded to Market Perform from Outperform at BMO Capital
T AT&T
$30.02 /

+0.38 (+1.28%)

05/21/21
Fly Intel: Top five analyst upgrades
05/21/21 New Street
New Street upgrades AT&T on 'tactical' call despite long-term concerns
05/21/21 New Street
AT&T upgraded to Buy from Neutral at New Street
05/21/21 UBS
AT&T upgraded to Buy from Neutral at UBS
PANW Palo Alto Networks
$362.50 /

+19.5 (+5.69%)

05/21/21 Northland
Palo Alto Networks price target raised to $440 from $420 at Northland
05/21/21 Raymond James
Palo Alto Networks price target raised to $410 from $400 at Raymond James
05/21/21 Deutsche Bank
Palo Alto Networks price target raised to $410 from $395 at Deutsche Bank
05/21/21 JPMorgan
Palo Alto Networks price target raised to $350 from $317 at JPMorgan
VIR Vir Biotechnology
$45.12 /

+0.14 (+0.31%)

03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
03/03/21 Goldman Sachs
Vir Biotechnology price target lowered to $59 from $61 at Goldman Sachs
03/03/21 H.C. Wainwright
Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
ANVS Annovis Bio
$81.75 /

+55.27 (+208.72%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
06/18/20 Maxim
Annovis Bio initiated with a Buy at Maxim
GSK GlaxoSmithKline
$38.91 /

-0.13 (-0.33%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
YALA Yalla
$18.20 /

+2.26 (+14.18%)

03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform on valuation at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform at Oppenheimer
FL Foot Locker
$61.49 /

+1.785 (+2.99%)

05/19/21 B. Riley
Foot Locker price target raised to $73 from $68 at B. Riley
05/18/21 Pivotal Research
Foot Locker price target raised to $76 from $61 at Pivotal Research
05/06/21 Citi
Foot Locker price target raised to $72 from $60 at Citi
04/08/21 Cowen
Foot Locker price target raised to $72 from $70 at Cowen
ONTX Onconova
$9.50 /

-1.411 (-12.93%)

05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
VFC VF Corp.
$78.44 /

-6.39 (-7.53%)

03/08/21 Pivotal Research
VF Corp. upgraded to Buy from Hold at Pivotal Research
02/22/21 Cowen
VF Corp. business positioned well for recovery, says Cowen
01/28/21 Deutsche Bank
VF Corp. price target lowered to $99 from $103 at Deutsche Bank
01/25/21 Cowen
VF Corp. price target raised to $99 from $91 at Cowen
VFC VF Corp.
$78.44 /

-6.39 (-7.53%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.50 /

+19.5 (+5.69%)

GSK GlaxoSmithKline
$38.91 /

-0.13 (-0.33%)

FL Foot Locker
$61.49 /

+1.785 (+2.99%)

DE Deere
$364.98 /

+9.91 (+2.79%)

  • 11
    Feb
  • 30
    Sep
  • 08
    Jul
YALA Yalla
$18.20 /

+2.26 (+14.18%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.50 /

+19.5 (+5.69%)

GSK GlaxoSmithKline
$38.91 /

-0.13 (-0.33%)

DE Deere
$364.98 /

+9.91 (+2.79%)

VIR Vir Biotechnology
$45.12 /

+0.14 (+0.31%)

VFC VF Corp.
$78.44 /

-6.39 (-7.53%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.50 /

+19.5 (+5.69%)

GSK GlaxoSmithKline
$38.91 /

-0.13 (-0.33%)

FL Foot Locker
$61.49 /

+1.785 (+2.99%)

DE Deere
$364.98 /

+9.91 (+2.79%)

YALA Yalla
$18.20 /

+2.26 (+14.18%)

VFC VF Corp.
$78.44 /

-6.39 (-7.53%)

T AT&T
$30.02 /

+0.38 (+1.28%)

PANW Palo Alto Networks
$362.50 /

+19.5 (+5.69%)

GSK GlaxoSmithKline
$38.91 /

-0.13 (-0.33%)

FL Foot Locker
$61.49 /

+1.785 (+2.99%)

DE Deere
$364.98 /

+9.91 (+2.79%)

Hot Stocks
Onconova announces initial dosing of first patient in Phase 1 trial of ON 123300 » 08:09
05/21/21
05/21
08:09
05/21/21
08:09
ONTX

Onconova

$10.91 /

-2.889 (-20.93%)

Onconova Therapeutics…

Onconova Therapeutics announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company's proprietary, novel multi-kinase inhibitor. The trial is expected to include three U.S. sites that will enroll patients with advanced cancer including, but not limited to, HR+ HER 2- metastatic breast cancer patients who are refractory to, or progressing on, currently approved CDK 4/6 inhibitors. The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of ON 123300 administered orally as monotherapy at increasing doses starting at 40 mg daily for consecutive 28-day cycles. Following completion of the dose-escalation phase of the trial and once the recommended Phase 2 dose is established, additional patients with HR+ HER 2- metastatic breast cancer with at least one prior line of therapy, which are expected to include approved CDK 4/6 inhibitors, will be enrolled into the trial with the intent to identify signals of efficacy. Additional cancer indications are also under consideration for study, and will be chosen based on preclinical and developing data.

ShowHide Related Items >><<
ONTX Onconova
$10.91 /

-2.889 (-20.93%)

ONTX Onconova
$10.91 /

-2.889 (-20.93%)

05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
  • 11
    Feb
Hot Stocks
Onconova announces one-for-fifteen reverse stock split » 09:03
05/20/21
05/20
09:03
05/20/21
09:03
ONTX

Onconova

/

+

Onconova Therapeutics…

Onconova Therapeutics announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021. Beginning at the open of trading on May 21, 2021, Onconova's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis. At Onconova's 2021 reconvened annual meeting of stockholders on April 30, 2021, Onconova stockholders authorized the Company's Board of Directors to amend the Tenth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio in the range of one-for-five to one-for-fifteen. Onconova's Board of Directors subsequently approved a reverse stock split ratio of one-for-fifteen, and the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation to effect the reverse stock split, which became effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware on May 20, 2021. Upon effectiveness of the reverse stock split, each fifteen shares of Onconova's common stock, par value of $0.01 per share, issued and outstanding immediately prior to the effective time automatically were reclassified, combined, converted and changed into one fully paid and non-assessable share of common stock, par value of $0.01 per share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options, warrants, and convertible preferred stock entitling the holders to purchase shares of our common stock. In particular, at the effective time of the reverse stock split, the Company adjusted its outstanding tradable warrants currently trading on the Nasdaq Capital Market under the symbol "ONTXW" in accordance with the terms of such tradable warrants to reflect the reverse stock split. As a result of these adjustments), each tradable warrant now entitles its holder to purchase one- two hundred and twenty-fifth of a share of Onconova's common stock at an exercise price of $1,107.00 per share of common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, Onconova's stockholders who otherwise would have been entitled to a fraction of a share, will receive a full share of common stock. If a holder of the tradable warrant would be entitled to receive a fraction of a share upon the exercise of the warrant, such fractional share will be rounded down to the nearest whole share. Fractional shares resulting from exercise of other common stock warrants and conversion of outstanding convertible preferred stock will be rounded in accordance with the terms of such securities. The reverse stock split will decrease the number of common shares issued and outstanding from approximately 236.714 million shares to approximately 15.781 million shares.

ShowHide Related Items >><<
ONTX Onconova
/

+

ONTX Onconova
/

+

05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
  • 11
    Feb
Initiation
Onconova initiated with a Buy at Guggenheim » 06:15
05/18/21
05/18
06:15
05/18/21
06:15
ONTX

Onconova

/

+

Guggenheim analyst Etzer…

Guggenheim analyst Etzer Darout initiated coverage of Onconova with a Buy rating and $4 price target.

ShowHide Related Items >><<
ONTX Onconova
/

+

ONTX Onconova
/

+

12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
08/24/20 Noble Capital
Onconova downgraded to Market Perform from Outperform at Noble Capital
  • 11
    Feb
Over a month ago
Hot Stocks
Onconova announces first patient dosed in phase 2 study of Rigosertib » 08:20
04/22/21
04/22
08:20
04/22/21
08:20
ONTX

Onconova

/

+

Onconova Therapeutics…

Onconova Therapeutics announced that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa, or RDEB, -associated locally advanced/metastatic squamous cell carcinoma, or SCC. The patient was dosed at the EB House Austria, a center of expertise for epidermolysis bullosa at the University Hospital Salzburg, Austria. Additional sites are anticipated to be opened in the UK and in the US to study this disease. In this open-label investigator-initiated study, 12 patients will receive either oral or intravenous rigosertib at the clinician's discretion given the various clinical manifestations of the disease, which may dictate the need for either oral or intravenous administration of rigosertib. Patients will receive either oral rigosertib in four-week cycles for up to 13 cycles, with 560 mg of oral rigosertib in the morning and again in the afternoon, for a total of 1,120 mg/day. Alternatively, patients will receive intravenous rigosertib as a 72-hour IV infusion on days 1, 2 and 3 of eight 2-week cycles, and on days 1, 2 and 3 of nine 4-week cycles thereafter, with each 24-hour infusion consisting of 1,800 mg of rigosertib. The study has two primary endpoints. The first is to determine the anti-tumor activity of rigosertib in RDEB patients with advanced SCC who have failed prior standard of care through the overall response rate, defined as the proportion of patients who achieve either a complete response or a partial response. The second primary endpoint is to evaluate the safety and tolerability of rigosertib in this population. Secondary study endpoints include quality of life and a biomarker analysis performed on archival tissue from all patients. Patients will be dosed for up to one year, with trial duration anticipated to be approximately two-and-a-half years.

ShowHide Related Items >><<
ONTX Onconova
/

+

ONTX Onconova
/

+

12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
08/24/20 Noble Capital
Onconova downgraded to Market Perform from Outperform at Noble Capital
ONTX Onconova
/

+

  • 11
    Feb
Hot Stocks
Onconova announces enrollment in Phase 1 study with ON 123300 in China » 08:03
04/01/21
04/01
08:03
04/01/21
08:03
ONTX

Onconova

$1.00 /

+0.0182 (+1.86%)

Onconova Therapeutics…

Onconova Therapeutics announces that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in HR+ HER2- metastatic breast cancer and other advanced relapsed/refractory cancers in China. The HanX trial has enrolled six patients to date in two cohorts and may continue to enroll patients with advanced relapsed/refractory cancer at increasing doses with three to six patients per dose until the recommended Phase 2 dose is identified. To date, patients have been dosed at the 40 mg and 80 mg dosage levels. HanX recently opened a third site, in Shanghai, for the conduct of the study.

ShowHide Related Items >><<
ONTX Onconova
$1.00 /

+0.0182 (+1.86%)

ONTX Onconova
$1.00 /

+0.0182 (+1.86%)

12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
08/24/20 Noble Capital
Onconova downgraded to Market Perform from Outperform at Noble Capital
ONTX Onconova
$1.00 /

+0.0182 (+1.86%)

  • 11
    Feb
Over a quarter ago
Hot Stocks
Onconova regains compliance with Nasdaq continued listing requirement » 08:17
02/24/21
02/24
08:17
02/24/21
08:17
ONTX

Onconova

$1.45 /

-0.095 (-6.15%)

Onconova Therapeutics…

Onconova Therapeutics announces receipt of notification from Nasdaq that the Company has regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) because the Company's common stock had a closing price of at least $1.00 per share for a minimum 10 consecutive business days. As previously reported, the Company was granted until April 5, 2021 to meet this requirement.

ShowHide Related Items >><<
ONTX Onconova
$1.45 /

-0.095 (-6.15%)

ONTX Onconova
$1.45 /

-0.095 (-6.15%)

12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
08/24/20 Noble Capital
Onconova downgraded to Market Perform from Outperform at Noble Capital
ONTX Onconova
$1.45 /

-0.095 (-6.15%)

  • 11
    Feb
ONTX Onconova
$1.45 /

-0.095 (-6.15%)

Syndicate
Onconova 25M share Spot Secondary priced at $1.00 » 05:01
02/11/21
02/11
05:01
02/11/21
05:01
ONTX

Onconova

$1.15 /

-0.055 (-4.56%)

Guggenheim acted as lead…

Guggenheim acted as lead book running manager for the offering.

ShowHide Related Items >><<
ONTX Onconova
$1.15 /

-0.055 (-4.56%)

ONTX Onconova
$1.15 /

-0.055 (-4.56%)

12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
08/24/20 Laidlaw
Onconova downgraded to Hold from Buy at Laidlaw
08/24/20 Maxim
Onconova downgraded to Hold from Buy at Maxim
08/24/20 Noble Capital
Onconova downgraded to Market Perform from Outperform at Noble Capital
ONTX Onconova
$1.15 /

-0.055 (-4.56%)

  • 11
    Feb
ONTX Onconova
$1.15 /

-0.055 (-4.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.